Phoenix Financial Ltd. increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 18.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,105 shares of the pharmaceutical company’s stock after buying an additional 1,112 shares during the quarter. Phoenix Financial Ltd.’s holdings in Vertex Pharmaceuticals were worth $3,715,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Summit Global Investments purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter worth approximately $3,568,000. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth approximately $13,823,000. UNIVEST FINANCIAL Corp purchased a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $4,495,000. State Street Corp grew its position in Vertex Pharmaceuticals by 1.2% during the second quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock valued at $5,896,910,000 after purchasing an additional 141,320 shares in the last quarter. Finally, Meeder Advisory Services Inc. purchased a new position in Vertex Pharmaceuticals during the second quarter valued at approximately $3,187,000. 90.96% of the stock is owned by institutional investors and hedge funds.
Vertex Pharmaceuticals Price Performance
Shares of Vertex Pharmaceuticals stock opened at $538.60 on Monday. The firm has a market cap of $136.56 billion, a price-to-earnings ratio of 34.66, a P/E/G ratio of 2.85 and a beta of 0.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.34 and a quick ratio of 1.89. Vertex Pharmaceuticals Incorporated has a 52-week low of $412.27 and a 52-week high of $568.67. The stock has a 50-day simple moving average of $522.37 and a 200-day simple moving average of $483.84.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The firm had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the firm posted $4.80 EPS. The company’s quarterly revenue was up 11.8% compared to the same quarter last year. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on VRTX. Weiss Ratings lowered shares of Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, November 9th. Canaccord Genuity Group lifted their target price on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research note on Tuesday, August 4th. Leerink Partners initiated coverage on shares of Vertex Pharmaceuticals in a report on Monday, September 21st. They set an “outperform” rating and a $594.00 price target on the stock. Daiwa Securities Group boosted their price target on shares of Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Finally, Jefferies Financial Group upped their price target on shares of Vertex Pharmaceuticals from $633.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $596.44.
View Our Latest Stock Report on VRTX
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Recommended Stories
- Five stocks we like better than Vertex Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
